Folr2+ macrophages and anti-tumor immunity
AssigneesInstitut Curie, Institut National de la Sante et de la Recherche Medicale, Université Paris Cité, Centre National De La Recherche Scientifique
InventorsRodrigo Nalio Ramos, Pierre Guermonprez, Eliane Piaggio, Julie Helft
Life of this patent
Estimating the term…
Abstract
The invention relates to tumor-associated FOLR2+ macrophages and gene signature thereof as a biomarker of favorable outcome and anti-tumor immunity useful for the prognosis and monitoring of cancer patients. The invention relates also to FOLR2+ macrophages as a therapeutic target for enhancing T cell immunity in the prevention and treatment of cancer and infectious diseases.
Claims21
1-16. (canceled)
A method of treating cancer in a patient, comprising:
- determining the level of FOLR2+ macrophages in a patient tumor sample, wherein the level of tumor-associated FOLR2+ macrophages correlates positively with outcome of cancer disease or treatment in the patient;
- deducing therefrom whether the outcome of cancer disease or treatment is likely to be favorable or unfavorable in the patient;
- and
- administering an appropriate treatment to the patient depending on whether the outcome of cancer disease or treatment is likely to be favorable or not in the patient.
A targeted antigen delivery system comprising a FOLR2 binding ligand associated with an antigen of interest or a nucleic acid encoding the antigen in expressible form.
A gene signature of tumor-associated FOLR2+ macrophages comprising or consisting of the FOLR2, SEPP1 and SLC40A1 genes.
Dependencies are inferred from the claim text.